• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 468459 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1416878687 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1416878687 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Bearish Moving Average Cross by Auxilium Pharmaceuticals (AUXL)

Published on Thu, 03/28/2013 - 11:13
By Adrienne Chilton

Today, shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) have fallen below their 10-day MA of $17.47 on a volume of 173K shares. Swing traders may find an opportunity for a short position, as such a crossover often suggests lower prices in the near term.

There is potential upside of 38.7% for shares of Auxilium Pharmaceuticals based on a current price of $17.30 and an average consensus analyst price target of $24.00. The stock should find initial resistance at its 50-day moving average (MA) of $17.77 and further resistance at its 200-day MA of $21.20.

Over the past year, Auxilium Pharmaceuticals has traded in a range of $16.25 to $29.37 and is now at $17.30, 6% above that low. In the last five trading sessions, the 50-day moving average (MA) has fallen 0.4% while the 200-day MA has slid 0.3%.

Auxilium Pharmaceuticals Inc. develops and commercializes pharmaceutical products that target urologic and sexual health disorders. The company's marketed product ,TESTIM, is a proprietary, topical 1% testosterone gel indicated for the treatment of hypogonadism.

By Adrienne Chilton
achilton@fnno.com

Latest News from FNNO

Shares of Weyerhaeuser Rise Above Previo...

Shares of Weyerhaeuser (NYSE:WY) traded at a new 52-week high today of $34.76. Approxi ...

Watch for Continued Gains in Shares of V...

Shares of VCA Antech (NASDAQ:WOOF) traded today at $47.00, breaking its 52-week high. ...

Recent 52-Week High Exceeded in Shares o...

Wells Fargo (NYSE:WFC) traded today at a new 52-week high of $54.36. Approximately 6.7 ...

Watch for Continued Gains in Shares of W...

Wabtec (NYSE:WAB) traded at a new 52-week high today of $91.14. So far today approxima ...

Ventas: 52-Week High Recently Eclipsed (...

Shares of Ventas (NYSE:VTR) traded today at $69.92, breaking its 52-week high. This ne ...

Recent 52-Week High Exceeded in Shares o...

Validus Holdings (NYSE:VR) traded today at a new 52-week high of $41.40. This new high ...

US Bancorp Looks to Continue to Trade Ab...

US Bancorp (NYSE:USB) traded today at a new 52-week high of $44.49. Approximately 3.2 ...

Union Pacific Looks to Continue to Trade...

Shares of Union Pacific (NYSE:UNP) traded at a new 52-week high today of $123.37. Appr ...